U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H12Cl2N4
Molecular Weight 343.21
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRIAZOLAM

SMILES

CC1=NN=C2CN=C(C3=C(Cl)C=CC=C3)C4=C(C=CC(Cl)=C4)N12

InChI

InChIKey=JOFWLTCLBGQGBO-UHFFFAOYSA-N
InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3

HIDE SMILES / InChI

Molecular Formula C17H12Cl2N4
Molecular Weight 343.21
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017892s038lbl.pdf

Triazolam is a short-acting benzodiazepine used as a hypnotic agent in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. Triazolam has a shorter half-life than chlordiazepoxide, flurazepam, and prazepam and does not generate active metabolites. Benzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. Triazolam is used for the short-term treatment of insomnia. Triazolam`s original brand name is Halcion. Triazolam is withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Halcion

Approved Use

Halcion is indicated for the short-term treatment of insomnia (generally 7–10 days). Use for more than 2–3 weeks requires complete reevaluation of the patient

Launch Date

4.06079996E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.75 ng/mL
0.25 mg single, oral
dose: 0.25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIAZOLAM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4.39 ng/mL
0.25 mg single, oral
dose: 0.25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIAZOLAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
13.05 ng × h/mL
0.25 mg single, oral
dose: 0.25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIAZOLAM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
13.78 ng × h/mL
0.25 mg single, oral
dose: 0.25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIAZOLAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.07 h
0.25 mg single, oral
dose: 0.25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIAZOLAM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.27 h
0.25 mg single, oral
dose: 0.25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIAZOLAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
3 mg single, oral
Highest studied dose
Dose: 3 mg
Route: oral
Route: single
Dose: 3 mg
Sources:
unhealthy, 21 - 60 years
n = 2
Health Status: unhealthy
Condition: insomnia
Age Group: 21 - 60 years
Sex: M
Population Size: 2
Sources:
Disc. AE: Ataxia, Drowsiness...
AEs leading to
discontinuation/dose reduction:
Ataxia (1 patient)
Drowsiness (1 patient)
Sources:
0.25 mg 1 times / day steady, oral
Recommended
Dose: 0.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 0.25 mg, 1 times / day
Sources:
unhealthy
n = 1003
Health Status: unhealthy
Condition: insomnia
Population Size: 1003
Sources:
Disc. AE: Coordination abnormal, Drowsiness...
AEs leading to
discontinuation/dose reduction:
Coordination abnormal
Drowsiness
Groggy
Somnolence
Depression
Restlessness
Dizziness
Lightheadedness
Headache
Nausea
Visual disturbance
Nervousness
Abdominal distress
Bladder disorders NEC
Aching in limb
Backache
Blepharitis
Sources:
AEs

AEs

AESignificanceDosePopulation
Ataxia 1 patient
Disc. AE
3 mg single, oral
Highest studied dose
Dose: 3 mg
Route: oral
Route: single
Dose: 3 mg
Sources:
unhealthy, 21 - 60 years
n = 2
Health Status: unhealthy
Condition: insomnia
Age Group: 21 - 60 years
Sex: M
Population Size: 2
Sources:
Drowsiness 1 patient
Disc. AE
3 mg single, oral
Highest studied dose
Dose: 3 mg
Route: oral
Route: single
Dose: 3 mg
Sources:
unhealthy, 21 - 60 years
n = 2
Health Status: unhealthy
Condition: insomnia
Age Group: 21 - 60 years
Sex: M
Population Size: 2
Sources:
Abdominal distress Disc. AE
0.25 mg 1 times / day steady, oral
Recommended
Dose: 0.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 0.25 mg, 1 times / day
Sources:
unhealthy
n = 1003
Health Status: unhealthy
Condition: insomnia
Population Size: 1003
Sources:
Aching in limb Disc. AE
0.25 mg 1 times / day steady, oral
Recommended
Dose: 0.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 0.25 mg, 1 times / day
Sources:
unhealthy
n = 1003
Health Status: unhealthy
Condition: insomnia
Population Size: 1003
Sources:
Backache Disc. AE
0.25 mg 1 times / day steady, oral
Recommended
Dose: 0.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 0.25 mg, 1 times / day
Sources:
unhealthy
n = 1003
Health Status: unhealthy
Condition: insomnia
Population Size: 1003
Sources:
Bladder disorders NEC Disc. AE
0.25 mg 1 times / day steady, oral
Recommended
Dose: 0.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 0.25 mg, 1 times / day
Sources:
unhealthy
n = 1003
Health Status: unhealthy
Condition: insomnia
Population Size: 1003
Sources:
Blepharitis Disc. AE
0.25 mg 1 times / day steady, oral
Recommended
Dose: 0.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 0.25 mg, 1 times / day
Sources:
unhealthy
n = 1003
Health Status: unhealthy
Condition: insomnia
Population Size: 1003
Sources:
Coordination abnormal Disc. AE
0.25 mg 1 times / day steady, oral
Recommended
Dose: 0.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 0.25 mg, 1 times / day
Sources:
unhealthy
n = 1003
Health Status: unhealthy
Condition: insomnia
Population Size: 1003
Sources:
Depression Disc. AE
0.25 mg 1 times / day steady, oral
Recommended
Dose: 0.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 0.25 mg, 1 times / day
Sources:
unhealthy
n = 1003
Health Status: unhealthy
Condition: insomnia
Population Size: 1003
Sources:
Dizziness Disc. AE
0.25 mg 1 times / day steady, oral
Recommended
Dose: 0.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 0.25 mg, 1 times / day
Sources:
unhealthy
n = 1003
Health Status: unhealthy
Condition: insomnia
Population Size: 1003
Sources:
Drowsiness Disc. AE
0.25 mg 1 times / day steady, oral
Recommended
Dose: 0.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 0.25 mg, 1 times / day
Sources:
unhealthy
n = 1003
Health Status: unhealthy
Condition: insomnia
Population Size: 1003
Sources:
Groggy Disc. AE
0.25 mg 1 times / day steady, oral
Recommended
Dose: 0.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 0.25 mg, 1 times / day
Sources:
unhealthy
n = 1003
Health Status: unhealthy
Condition: insomnia
Population Size: 1003
Sources:
Headache Disc. AE
0.25 mg 1 times / day steady, oral
Recommended
Dose: 0.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 0.25 mg, 1 times / day
Sources:
unhealthy
n = 1003
Health Status: unhealthy
Condition: insomnia
Population Size: 1003
Sources:
Lightheadedness Disc. AE
0.25 mg 1 times / day steady, oral
Recommended
Dose: 0.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 0.25 mg, 1 times / day
Sources:
unhealthy
n = 1003
Health Status: unhealthy
Condition: insomnia
Population Size: 1003
Sources:
Nausea Disc. AE
0.25 mg 1 times / day steady, oral
Recommended
Dose: 0.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 0.25 mg, 1 times / day
Sources:
unhealthy
n = 1003
Health Status: unhealthy
Condition: insomnia
Population Size: 1003
Sources:
Nervousness Disc. AE
0.25 mg 1 times / day steady, oral
Recommended
Dose: 0.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 0.25 mg, 1 times / day
Sources:
unhealthy
n = 1003
Health Status: unhealthy
Condition: insomnia
Population Size: 1003
Sources:
Restlessness Disc. AE
0.25 mg 1 times / day steady, oral
Recommended
Dose: 0.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 0.25 mg, 1 times / day
Sources:
unhealthy
n = 1003
Health Status: unhealthy
Condition: insomnia
Population Size: 1003
Sources:
Somnolence Disc. AE
0.25 mg 1 times / day steady, oral
Recommended
Dose: 0.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 0.25 mg, 1 times / day
Sources:
unhealthy
n = 1003
Health Status: unhealthy
Condition: insomnia
Population Size: 1003
Sources:
Visual disturbance Disc. AE
0.25 mg 1 times / day steady, oral
Recommended
Dose: 0.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 0.25 mg, 1 times / day
Sources:
unhealthy
n = 1003
Health Status: unhealthy
Condition: insomnia
Population Size: 1003
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
yes
yes
yes (co-administration study)
Comment: contraindicated with strong CYP3A inhibitors such as ketoconazole, itraconazole, nefazodone, ritonavir, indinavir, nelfinavir, saquinavir, and lopinavir; from 2019 label: grapefruit juice increased maximum plasma concentration of triazolam by 25% and increased AUC by 48%
Page: 7.0
PubMed

PubMed

TitleDatePubMed
Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general.
1999 May-Aug
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
2000 Jan 13
Topological alteration of the CYP3A4 active site by the divalent cation Mg(2+).
2000 Oct
Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site.
2001
Brain glycine levels in triazolam-treated albino rats.
2001
Zolpidem, triazolam, and diazepam decrease distress vocalizations in mouse pups: differential antagonism by flumazenil and beta-Carboline-3-carboxylate-t-butyl ester (beta-CCt).
2001 Apr
Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site.
2001 Jan
Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains.
2001 Jul 1
Sleep inducing effects of propofol microinjection into the medial preoptic area are blocked by flumazenil.
2001 Jul 27
The hypnotic effect of propofol in the medial preoptic area of the rat.
2001 Jul 6
Benzodiazepines as a social problem: the case of halcion.
2001 Jul-Aug
A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects.
2001 Jun
Hypnotic action of melatonin during daytime administration and its comparison with triazolam.
2001 Jun
Pharmacokinetics and clinical effects of sublingual triazolam in pediatric dental patients.
2001 Jun
Behavioral effects of flunitrazepam: reinforcing and discriminative stimulus effects in rhesus monkeys and prevention of withdrawal signs in pentobarbital-dependent rats.
2001 Jun 1
Investigation of preference for nightly triazolam versus placebo in moderate social alcohol drinkers.
2001 Mar
CYP3A inductive potential of the rifamycins, rifabutin and rifampin, in the rabbit.
2001 May
Circadian phase shifting: Relationships between photic and nonphotic phase-response curves.
2001 May
Functional pharmacology of GABA(A) receptors containing the chicken brain gamma 4 subunit.
2001 May 4
Isobolographic analysis of chlordiazepoxide and triazolam combinations in squirrel monkeys discriminating triazolam.
2001 Nov
The hypnotic actions of the fatty acid amide, oleamide.
2001 Nov
Effects of triazolam on brain activity during episodic memory encoding: a PET study.
2001 Nov
Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo.
2001 Sep
Sensitive method for the detection of 22 benzodiazepines by gas chromatography-ion trap tandem mass spectrometry.
2002 Apr 19
[Pharmacological profile and clinical effect of zolpidem (Myslee tablets), a hypnotic agent].
2002 Feb
Distribution of triazolam and alpha-hydroxytriazolam in a fatal intoxication case.
2002 Jan-Feb
Daily treatment with diazepam differentially modifies sensitivity to the effects of gamma-aminobutyric acid(A) modulators on schedule-controlled responding in rhesus monkeys.
2002 Mar
Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes.
2002 May
Disposition of triazolam in the rat by brain microdialysis and semi-micro column high-performance liquid chromatography with UV absorbance detection.
2002 May
Effects of triazolam, 8-OH-DPAT, and buspirone on repeated acquisition in squirrel monkeys.
2002 Nov
Transnational industrial power, the medical profession and the regulatory state: adverse drug reactions and the crisis over the safety of Halcion in the Netherlands and the UK.
2002 Nov
Interactions between recreational drugs and antiretroviral agents.
2002 Oct
Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes.
2002 Sep 13
Melatonin microinjection into the medial preoptic area increases sleep in the rat.
2002 Sep 13
Pharmacokinetic interactions with rifampicin : clinical relevance.
2003
[Cytochrome P450 3A4 and Benzodiazepines].
2003
Clinically important drug interactions with zopiclone, zolpidem and zaleplon.
2003
Clinical pharmacokinetic profile of modafinil.
2003
Discriminative-stimulus effects of triazolam in light and moderate drinkers.
2003 Apr
A study into the rate of incorporation of eight benzodiazepines into rat hair.
2003 Apr 23
[Diagnostics and treatment of sleep disorders in elderly people].
2003 Apr-Jun
Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole.
2003 Jan 15
Effects of short-acting hypnotics on sleep latency in rats placed on grid suspended over water.
2003 Jan 24
In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.
2003 Jul
Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital.
2003 Jun
Selective effects of triazolam on memory for emotional, relative to neutral, stimuli: differential effects on gist versus detail.
2003 Jun
Role of platelet activating factor in triazolobenzodiazepines-induced retrograde amnesia.
2003 Jun 16
Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.
2003 Mar
Anxiolysis in general dental practice.
2003 Mar
Triazolam-amphetamine interaction: dissociation of effects on memory versus arousal.
2003 Mar
Patents

Sample Use Guides

In Vivo Use Guide
The recommended dose for most adults is 0.25 mg before retiring. A dose of 0.125 mg may be found to be sufficient for some patients (e.g., low body weight). A dose of 0.5 mg should be used only for exceptional patients who do not respond adequately to a trial of a lower dose since the risk of several adverse reactions increases with the size of the dose administered. A dose of 0.5 mg should not be exceeded.
Route of Administration: Oral
In Vitro Use Guide
Triazolam inhibited [3H]flunitrazepam binding with an IC50 value of 0.85 nM and a Ki value of 0.50 nM in mice.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:53:18 UTC 2023
Edited
by admin
on Wed Jul 05 22:53:18 UTC 2023
Record UNII
1HM943223R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRIAZOLAM
HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
USAN   INN  
Official Name English
TRIAZOLAM [HSDB]
Common Name English
N05CD05
Code English
TRIAZOLAM [JAN]
Common Name English
U-33,030
Code English
TRIAZOLAM [MART.]
Common Name English
TRIAZOLAM [VANDF]
Common Name English
4H-(1,2,4)TRIAZOLO(4,3-A)(1,4)BENZODIAZEPINE, 8-CHLORO-6-(2-CHLOROPHENYL)-1-METHYL-
Systematic Name English
Triazolam [WHO-DD]
Common Name English
TRIAZOLAM [MI]
Common Name English
U-33030
Code English
triazolam [INN]
Common Name English
TRIAZOLAM [USAN]
Common Name English
TRIAZOLAM [ORANGE BOOK]
Common Name English
TRIAZOLAM [USP MONOGRAPH]
Common Name English
8-CHLORO-6-(O-CHLOROPHENYL)-1-METHYL-4H-S-TRIAZOLO(4,3-A)(1,4)BENZODIAZEPINE
Common Name English
TRIAZOLAM CIV [USP-RS]
Common Name English
HALCION
Brand Name English
TRIAZOLAM CIV
USP-RS  
Common Name English
Classification Tree Code System Code
WHO-VATC QN05CD05
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
NDF-RT N0000007542
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
NCI_THESAURUS C1012
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
NDF-RT N0000175694
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
LIVERTOX NBK547843
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
DEA NO. 2887
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
WHO-ATC N05CD05
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
Code System Code Type Description
FDA UNII
1HM943223R
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
HSDB
6759
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
DRUG CENTRAL
2729
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
DRUG BANK
DB00897
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
EPA CompTox
DTXSID6046763
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
MERCK INDEX
M11035
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY Merck Index
SMS_ID
100000092518
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
ECHA (EC/EINECS)
249-307-3
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
WIKIPEDIA
TRIAZOLAM
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
ChEMBL
CHEMBL646
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
PUBCHEM
5556
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
CAS
28911-01-5
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
INN
3409
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
MESH
D014229
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
RXCUI
10767
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY RxNorm
IUPHAR
7313
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
LACTMED
Triazolam
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
RS_ITEM_NUM
1680506
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
NCI_THESAURUS
C29520
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
CHEBI
9674
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
EVMPD
SUB11258MIG
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
DAILYMED
1HM943223R
Created by admin on Wed Jul 05 22:53:18 UTC 2023 , Edited by admin on Wed Jul 05 22:53:18 UTC 2023
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC